Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
Checkpoint inhibitors are first-line therapies in melanoma, but safety in older adults has not yet been assessed. Ipilimumab improves survival, but immunologic-related adverse events (AEs) can be threatening, and its use in elderly people raises questions.
To assess safety in a cohort of very elderly patients treated with ipilimumab.
All patients over 80 years treated with ipilimumab for melanoma were retrospectively included. AE occurrence, management, and outcome, as well as response rate at week 16 and overall survival were recorded, and compared to data for a group of younger patients treated in our institution during the same period.
In the elderly group, 23 patients were included with a median age of 82 years [80–90]. AEs amounting to 23 occurred in 15 patients (65%) with 5 grade 3 (22%) and 1 grade 5 (opportunistic infection) AEs. Corticosteroids were required for five (22%) patients, additive immunosuppressive therapy for two, hospitalization for four, and definitive interruption of ipilimumab for three. Median overall survival was 14 months. In the younger group, 29 patients were included with a median age of 58 years. AEs occurred in 15/29 (52%) with 4 grade 3 (19%) and 1 grade 4 (7%). Median OS was 17 months.
Serious AEs occurred in 80 + adults at the same rate as observed in our younger patients and as previously reported in younger populations. Ipilimumab can be an option in elderly patients, as patients may benefit from therapy and safety seems to be manageable.
KeywordsIpilimumab Checkpoint inhibitors Elderly Older adults Adverse events Melanoma
Anti-tumor-necrosis-factor alpha inhibitors
- CT scan
Computed tomography scan
- ECOG status
Eastern Cooperative Oncology Group status
Immunologic-related adverse events
Randomized clinical trials
Tumor node metastasis
We thank Dr Marie-Laure Jullie, Pathology Department, CHU Bordeaux, France, for language editing of the manuscript.
All the authors had full access to all the data in the study. Manuscript was prepared by Vaianu Leroy, Emilie Gerard and Anne Pham-Ledard. Clinical data were prepared and interpreted by Vaianu Leroy, Emilie Gerard, Caroline Dutriaux, Sorilla Prey, Aurelia Gey, Marie Beylot-Barry, Cecile Mertens, and Anne Pham-Ledard. Marie Beylot-Barry and Anne Pham-Ledard reviewed the paper and provided important advice.
No relevant funding.
Compliance with ethical standards
Conflict of interest
Consulting and advisory role for Bristol-Myers Squibb (Dutriaux, Beylot-Barry); speaker honorarium (Pham-Ledard, Dutriaux, Beylot-Barry) travelling, expenses and accommodation (Pham-Ledard, Dutriaux, Beylot-Barry, Prey). All other authors declare that they have no conflict of interest.
A written informed consent was obtained from all individual participants included in the study, allowing authors to exploit data anonymously.
Ethical approval and ethical standards
This study has been approved by the ethics committee of the University Hospital of Bordeaux, reference number GP-CE2018/11, and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
- 4.Horvat TZ, Adel NG, Dang T-O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193–3198. https://doi.org/10.1200/JCO.2015.60.8448 CrossRefGoogle Scholar
- 5.Kaehler KC, Piel S, Livingstone E et al (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37:485–498. https://doi.org/10.1053/j.seminoncol.2010.09.003 CrossRefGoogle Scholar
- 6.Chiarion Sileni V, Pigozzo J, Ascierto PA et al (2014) Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 33:30. https://doi.org/10.1186/1756-9966-33-30 CrossRefGoogle Scholar